EPCAM and Familial prostate cancer: In fact, although it is difficult to detect the EpCAM marker in early prostate cancer, an experience on the Adnatest platform was published, identifying CTCs even in patients with low-risk clinically localized prostate cancer (22.2%) and high-risk clinically localized prostate cancer (30.9%), showing that EpCAM CTCs, already with epithelial characteristics, can be detected in the context of early-stage PC [52].